Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573417 | 0.83 | BACE1 (0.49) | BACE1ALDH1A1POLBHPGD | |
| SCHEMBL7993318 | 0.81 | BACE1 (0.51) | BACE1CES2CES1ALDH1A1POLB | |
| SCHEMBL6546743 | 0.79 | BACE1 (0.46) | BACE1ALDH1A1POLBKDM4EGAA | |
| SCHEMBL8323836 | 0.77 | BACE1 (0.65) | BACE1ALDH1A1KDM4ECYP1A2CYP2C19 | |
| SCHEMBL18618230 | 0.77 | ALDH1A1 (0.45) | BACE1ALDH1A1KDM4ETSHR | |
| SCHEMBL31388681 | 0.76 | LMNA (0.43) | BACE1ALDH1A1GAACYP2C19 | |
| SCHEMBL13516362 | 0.74 | BACE1 (0.47) | BACE1 | |
| SCHEMBL3562787 | 0.73 | BACE1 (0.46) | BACE1ALDH1A1 | |
| SCHEMBL13516354 | 0.72 | FLT1 (0.42) | BACE1ALDH1A1GAAHPGDCYP1A2 | |
| SCHEMBL9370645 | 0.71 | MAPK1 (0.54) | BACE1ALDH1A1POLBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742904-B1 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7825278-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | GABRB2, GABRB1, GABRB3 | BACE1 696/4885CES2 1007/4885CES1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.